Truist Financial
IBRX icon

Truist Financial’s ImmunityBio IBRX Stock Holding History

Truist Financial’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$482K Hold
55,055
– – ﹤0.01% 2223
2026
Q1 		$422K Buy
55,055
+45,055
+451% +$308K ﹤0.01% 2176
2025
Q4 		$19.8K Sell
10,000
-900
-8% -$2.04K ﹤0.01% 2748
2025
Q3 		$26.8K Buy
+10,900
New +$28.1K ﹤0.01% 2698
2020
Q3 		– Sell
-24,110
Closed -$296K – 2487
2020
Q2 		$296K Buy
+24,110
New +$136K ﹤0.01% 1955

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.36B AUM 18.79% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 14.43% 1-Year Est. Return
KA
Kercheville Advisors San Antonio, Texas $328M AUM 76.85% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Truist Financial's IBRX Position: Q2 2026 in Review

Truist Financial held its ImmunityBio (IBRX) position steady in Q2 2026 at 55,055 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #2223.

Truist Financial first reported a position in IBRX in Q2 2020 and has held it in 5 quarters since. 205 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Truist Financial held 55,055 shares of ImmunityBio worth $482K as of Q2 2026.
  • Truist Financial left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2223 holding.
  • Truist Financial first reported a position in ImmunityBio in Q2 2020 and has held it in 5 quarters since.
  • 205 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.